SmithKline Beecham to conduct Phase IV Nicotrol safety/efficacy study in adolescents.
This article was originally published in The Tan Sheet
Executive Summary
NICOTROL PATCH PHASE IV COMMITMENTS INCLUDE SURVEILLANCE OF SALES TO MINORS and a study of the safety and efficacy of Nicotrol use in adolescents, FDA reminded McNeil in its recent approval letter for the Rx-to-OTC switch nicotine patch therapy. The requirements are nearly identical to those for the other smoking cessation aid recently switched to OTC status -- SmithKline Beecham's Nicorette nicotine replacement chewing gum ("The Tan Sheet" Feb. 19, p. 5).
You may also be interested in...
GSK Commit Lozenge Phase IV Studies On Contraindications, AEs Planned
GlaxoSmithKline's Phase IV obligations for its Commit nicotine polacrilex lozenge include a study of consumers who are contraindicated for use of the OTC smoking cessation drug due to underlying health conditions, FDA's Oct. 31 approval letter states
GSK Commit Lozenge Phase IV Studies On Contraindications, AEs Planned
GlaxoSmithKline's Phase IV obligations for its Commit nicotine polacrilex lozenge include a study of consumers who are contraindicated for use of the OTC smoking cessation drug due to underlying health conditions, FDA's Oct. 31 approval letter states
GSK Commit Lozenge Phase IV Studies On Contraindications, AEs Planned
GlaxoSmithKline's Phase IV obligations for its Commit nicotine polacrilex lozenge include a study of consumers who are contraindicated for use of the OTC smoking cessation drug due to underlying health conditions, FDA's Oct. 31 approval letter states